Robert Weisman

Weisman covers the healthcare and life sciences industries for the Business section. He was a business reporter and editor for the Hartford Courant and the Seattle Times before joining the Globe in 2000.

Latest stories

Repligen agrees to buy Spectrum for $359 million

By , Globe Staff

Waltham life sciences company Repligen Corp. said it agreed to pay $359 million to acquire Spectrum Laboratories Inc.

Syntimmune raises $50 million to advance drug programs

By , Globe Staff

Four-year-old Waltham biotech Syntimmune Inc. said Wednesday it has closed a $50 million funding round that will enable it to press forward with its drug development programs, including clinical trials of its lead drug candidate to treat autoimmune diseases.

Biotech startup Rubius raises $120m to develop red blood cell technology

By , Globe Staff

The funding will let Rubius step up work on its drug discovery technique, which genetically engineers red blood cells so they can produce drugs for a range of diseases.

Parexel sold for $5 billion to private equity firm

By , Globe Staff

The Waltham-based operation is one of the largest companies performing contract research and managing clinical trials for drug makers.